Amgen and Allergan were granted marketing authorization from the European Commission for MVASI (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with chemotherapy or other therapies for metastatic carcinoma of the colon or rectum, metastatic breast cancer, non-squamous non-small cell lung cancer (NSCLC), renal cell cancer, ovarian, fallopian tube, or primary peritoneal can...